Dale Greiner to Treatment Outcome
This is a "connection" page, showing publications Dale Greiner has written about Treatment Outcome.
Connection Strength
0.056
-
Yang J, Jiao J, Draheim KM, Yang G, Yang H, Yao LC, Shultz LD, Greiner DL, Rajagopal D, Vessillier S, Maier CC, Mohanan S, Cai D, Cheng M, Brehm MA, Keck JG. Simultaneous evaluation of treatment efficacy and toxicity for bispecific T-cell engager therapeutics in a humanized mouse model. FASEB J. 2023 06; 37(6):e22995.
Score: 0.026
-
Trabucco SE, Gerstein RM, Evens AM, Bradner JE, Shultz LD, Greiner DL, Zhang H. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin Cancer Res. 2015 Jan 01; 21(1):113-22.
Score: 0.014
-
Kruger AJ, Yang C, Lipson KL, Pino SC, Leif JH, Hogan CM, Whalen BJ, Guberski DL, Lee Y, Unger RH, Greiner DL, Rossini AA, Bortell R. Leptin treatment confers clinical benefit at multiple stages of virally induced type 1 diabetes in BB rats. Autoimmunity. 2011 Mar; 44(2):137-48.
Score: 0.011
-
Ballen KK, Valinski H, Greiner D, Shultz LD, Becker PS, Hsieh CC, Stewart FM, Quesenberry PJ. Variables to predict engraftment of umbilical cord blood into immunodeficient mice: usefulness of the non-obese diabetic--severe combined immunodeficient assay. Br J Haematol. 2001 Jul; 114(1):211-8.
Score: 0.006